Recombinant human interferon α2b injection

Pharmacology: Recombinant human interferon alpha 2b has broad-spectrum antiviral, anti-tumor, cell proliferation inhibition and immune function enhancement effects. Interferon binds to cell surface receptors, induces cells to produce a variety of antiviral proteins, inhibits virus reproduction in cells, and improves immune function, including enhancing the phagocytic function of macrophages, enhancing the cytotoxicity of lymphocytes to target cells and the function of natural killer cells. Toxicology: Acute toxicity test: The product was injected intraperitoneally and intravenously into mice, with the dosage of 1.5 times 109 IU/kg and 1.5 times 108 IU/kg, respectively, which is 105 and 104 times the therapeutic dose for humans. No acute poisoning symptoms occurred, and no animals died.

Main ingredients: recombinant human interferon alpha; 2b, human serum albumin.

1. Viral diseases: adult patients with chronic active hepatitis B accompanied by viral replication markers such as HBV-DNA, DNA polymerase positive or HBeAg positive, adult patients with acute and chronic hepatitis C accompanied by positive HCV antibodies and increased alanine aminotransferase (ALT) but without liver function decompensation (Child classification A), genital warts, herpes zoster, pediatric viral pneumonia and upper respiratory tract infection, chronic cervicitis, hepatitis D, etc.; 2. Tumors: hairy cell leukemia, multiple myeloma, non-Hodgkin's lymphoma, chronic leukemia, Kaposi's sarcoma, renal cancer, laryngeal papilloma, melanoma, mycosis fungoides, bladder cancer, basal cell carcinoma, etc.

This product can be injected intramuscularly, subcutaneously and into the lesion. 1 Chronic hepatitis B: subcutaneous or intramuscular injection, 3-6106IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks. 2 Acute and chronic hepatitis C: subcutaneous or intramuscular injection, 3-6106IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks. 3 Hepatitis D: subcutaneous or intramuscular injection, 4-5106IU/day, change to 3 times/week after four weeks of continuous use, and continue for more than 16 weeks. 4 Herpes zoster: intramuscular injection, 1106IU/day, for 6 consecutive days, and oral acyclovir. 5 Genital warts: can be used alone, intramuscular injection, 1-3106IU/day, for four weeks. It can also be used in combination with laser or electrocautery, generally injected at the base of the wart, 1106IU/time. 6 Hairy cell leukemia: 2-8106IU/m2/day, continuous use for at least 3 months. 7 Chronic myeloid leukemia: 3-5106IU/m2/day, intramuscular injection. Can be used in combination with chemotherapy drugs such as hydroxyurea and Ara-c. 8 Multiple myeloma: As induction or maintenance therapy, 3-5106IU/m2, intramuscular injection, 3 times/week, and combined with chemotherapy regimens such as VMCP. 9 Non-Hodgkin's lymphoma: As induction or maintenance therapy, 3-5106IU/m2, intramuscular injection, 3 times/week, and combined with chemotherapy regimens such as CHVP. 10 Malignant melanoma: 6106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs. 11 Renal cell carcinoma: 6106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs. 12 Laryngeal papilloma: 3106IU/m2, intramuscular injection or subcutaneous injection, 3 times a week (once every other day). 13 Kaposi's sarcoma: 50106IU/m2/day, for 5 consecutive days, intravenous drip for 30 minutes each time. At least 9 days interval before the next 5-day treatment period. 14 Basal cell carcinoma: 5106IU, intratumoral injection, 3 times/week, 3 weeks. 15 Ovarian cancer: 5-8106IU, intramuscular injection, 3 times/week, combined with chemotherapy drugs.

Common symptoms of this product include fever, headache, chills, fatigue, myalgia, and joint pain, which often occur in the first week of medication. Adverse reactions usually disappear 48 hours after injection. In case of serious adverse reactions, the treatment plan must be modified or the medication must be stopped. If an allergic reaction occurs, the medication should be stopped immediately. A small number of patients may experience abnormal blood counts such as leukopenia and thrombocytopenia, which can return to normal after stopping the medication. Occasionally, adverse reactions such as anorexia, nausea, diarrhea, vomiting, hair loss, increased or decreased blood pressure, and nervous system dysfunction are seen.

1. Those with a history of allergy to recombinant human interferon α2a or any component of the preparation; 2. Those with severe heart disease or a history of heart disease; 3. Those with severe liver, kidney or bone marrow dysfunction; 4. Those with epilepsy and central nervous system damage; 5. Hepatitis patients with advanced decompensated liver disease or cirrhosis; 6. Chronic hepatitis patients who are currently receiving or will receive immunosuppressant treatment in the near future, except for short-term "hormone-free" treatment; 7. HLA antibody-recognition-associated chronic myeloid leukemia patients who are about to receive allogeneic bone marrow transplantation.

Interferon may change the activity of some enzymes, especially reduce the activity of cytochrome P450, thus affecting the metabolism of drugs such as cimetidine, warfarin, theophylline, diazepam, propranolol, etc. When used in combination with drugs with central nervous system effects, interactions may occur.

Store at 2-8℃ away from light.

10 million IU/1.0ml

ChangChun Heber Biological Technology Co., Ltd.

• Founded in:

  2003-12-08

• Address:

  No. 11111, Gangcheng Street, Airport Economic Development Zone, Changchun New Area, Jilin Province

• Tax NO.:

  91220101748448227C

• Registered Funds:

  383.634129 yuan

• Website:

  Log in to view

• Email:

  Log in to view